The rapid development and distribution of highly efficacious messenger ribonucleic acid (mRNA) vaccines has been regarded as a great success, especially during the ongoing pandemic. As COVID-19 cases continue to soar in some countries, demand for Pfizer and Moderna 's vaccines is fast exceeding production capabilities. Restrictions placed on AstraZeneca and Johnson & Johnson 's adenovirus-based vaccines due to links with rare blood clots have placed additional pressures on global vaccine rollouts, particularly in Europe. Curevac 's expected entry into the COVID-19 vaccine market may provide a viable alternative and help address vaccine inequality because of its vaccine's unique properties.